Literature DB >> 9542791

MRI correlates of treatment response in first episode psychosis.

R B Zipursky1, J Zhang-Wong, E K Lambe, G Bean, M Beiser.   

Abstract

It is not known whether the magnitude of the structural brain abnormalities that underlie schizophrenia is a determinant of the extent to which patients respond to antipsychotic medication. This study was undertaken in order to explore this relationship. Twenty-six patients receiving treatment for a first episode of psychosis were involved in both a study measuring treatment response and a magnetic resonance imaging (MRI) study. In the treatment study, haloperidol dose was increased weekly beginning at 2 mg/day until patients showed evidence of a response or extrapyramidal symptoms. MRI scans were analyzed using a computerized volumetric approach to yield estimates of cerebrospinal fluid (CSF), gray-matter and white-matter volumes. Improvement in positive and negative symptoms after 1 week of treatment was significantly correlated with cortical gray-matter volumes. Those patients who were maintained on 2 mg/day of haloperidol had greater cortical gray-matter volume than those who were treated with higher doses. The severity of structural brain abnormalities at the onset of psychosis may contribute to individual variation in response to antipsychotic medication. It remains to be determined whether the degree to which particular domains of symptomatology can improve is related to the severity of structural brain pathology in specific brain regions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9542791     DOI: 10.1016/s0920-9964(97)00126-6

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  10 in total

1.  Functional neuroimaging in mental disorders.

Authors:  Philip K McGuire; Kazunori Matsumoto
Journal:  World Psychiatry       Date:  2004-02       Impact factor: 49.548

2.  Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia.

Authors:  Philip R Szeszko; Katherine L Narr; Owen R Phillips; Joanne McCormack; Serge Sevy; Handan Gunduz-Bruce; John M Kane; Robert M Bilder; Delbert G Robinson
Journal:  Schizophr Bull       Date:  2010-11-17       Impact factor: 9.306

Review 3.  Neuroimaging markers of antipsychotic treatment response in schizophrenia: An overview of magnetic resonance imaging studies.

Authors:  Goda Tarcijonas; Deepak K Sarpal
Journal:  Neurobiol Dis       Date:  2018-06-25       Impact factor: 5.996

4.  Optimized voxel brain morphometry: association between brain volumes and the response to atypical antipsychotics.

Authors:  Vicente Molina; Carmen Martín; Alejandro Ballesteros; Alba G Seco de Herrera; Juan Antonio Hernández-Tamames
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-12-30       Impact factor: 5.270

Review 5.  A review of MRI findings in schizophrenia.

Authors:  M E Shenton; C C Dickey; M Frumin; R W McCarley
Journal:  Schizophr Res       Date:  2001-04-15       Impact factor: 4.939

Review 6.  Magnetic resonance imaging and the prediction of outcome in first-episode schizophrenia: a review of current evidence and directions for future research.

Authors:  Paola Dazzan; Celso Arango; Wolfgang Fleischacker; Silvana Galderisi; Birte Glenthøj; Stephan Leucht; Andreas Meyer-Lindenberg; Rene Kahn; Dan Rujescu; Iris Sommer; Inge Winter; Philip McGuire
Journal:  Schizophr Bull       Date:  2015-03-23       Impact factor: 7.348

7.  Patients with poor response to antipsychotics have a more severe pattern of frontal atrophy: a voxel-based morphometry study of treatment resistance in schizophrenia.

Authors:  Mario Quarantelli; Olga Palladino; Anna Prinster; Vittorio Schiavone; Barbara Carotenuto; Arturo Brunetti; Angela Marsili; Margherita Casiello; Giovanni Muscettola; Marco Salvatore; Andrea de Bartolomeis
Journal:  Biomed Res Int       Date:  2014-07-23       Impact factor: 3.411

Review 8.  Neuroimaging biomarkers to predict treatment response in schizophrenia: the end of 30 years of solitude?

Authors:  Paola Dazzan
Journal:  Dialogues Clin Neurosci       Date:  2014-12       Impact factor: 5.986

9.  PKBγ/AKT3 loss-of-function causes learning and memory deficits and deregulation of AKT/mTORC2 signaling: Relevance for schizophrenia.

Authors:  Kristy R Howell; Kirsten Floyd; Amanda J Law
Journal:  PLoS One       Date:  2017-05-03       Impact factor: 3.240

Review 10.  Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review.

Authors:  Amy L Gillespie; Ruta Samanaite; Jonathan Mill; Alice Egerton; James H MacCabe
Journal:  BMC Psychiatry       Date:  2017-01-13       Impact factor: 3.630

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.